Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...

Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All participants have been placed in a listen-only mode. You'll have an ...

Syndax Pharmaceuticals (SNDX) and Royalty Pharma (RPRX) announced that Syndax has entered into a $350M synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo.

"This has been a historic period for Syndax as we transitioned to a commercial-stage company with the approval of Niktimvo. With the recently completed royalty financing, we expect to be funded ...

Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no ...

The US regulator has cleared the anti-CSF-1R antibody under the Niktimvo brand for the treatment of chronic GvHD after failure of at least two prior lines of systemic therapy in adult and ...

Greetings, and welcome to the Incyte third-quarter financial results conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...